Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07693569 · ClinicalTrials.gov registry record · Early Phase 1
Collagenase Injection for Spasticity Management
A Early Phase 1 study, sponsored by The University of Texas Health Science Center, Houston.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
NCT07693569: Clinical Trial Early Phase 1 study, sponsored by The University of Texas Health Science Center, Houston.
NCT07693569 is a Early Phase 1 study that has not yet begun recruiting, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 15 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07693569, a Early Phase 1 study, has not yet begun recruiting, sponsored by The University of Texas Health Science Center, Houston.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The overall goal is to investigate the effectiveness of a novel intervention - Collagenase injection, for spasticity management in patients with neurological impairments, such as stroke, brain injury, and spinal cord injury.
Primary Outcome
The Modified Ashworth Scale (MAS) evaluates the increase in muscle tone associated with upper motor neuron lesions. MAS scores will be recorded for the target muscle group(s) at each assessment time point.Scores range from 0 to 4, with an additional grade of 1+ between 1 and 2. Scores are defined as: 0 = no increase in muscle tone; 1 = slight increase in muscle tone with a catch and release or minimal resistance at the end of the range of motion; 1+ = slight increase in muscle tone with a catch
Interventions
- BIOLOGICAL XIAFLEX Collagenase injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2031-09-30 |
| Phase | Early Phase 1 |
What is known before NCT07693569 opens enrollment
NCT07693569 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 1 intervention - of which XIAFLEX Collagenase injection is the first listed.
NCT07693569 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07693569 about?
NCT07693569 is a clinical study titled "Collagenase Injection for Spasticity Management". The overall goal is to investigate the effectiveness of a novel intervention - Collagenase injection, for spasticity management in patients with neurological impairments, such as stroke, brain injury, and spinal cord injury.
What is the current status of trial NCT07693569?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2026-09-01. Estimated completion is 2031-09-30.
What interventions are being tested in trial NCT07693569?
The interventions under investigation include: XIAFLEX Collagenase injection (BIOLOGICAL).
Who is sponsoring clinical trial NCT07693569?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07693569's enrollment target sits among peer trials
15 1403rd of 2000 higher than 527 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI